You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 273 No. 7, February 15, 1995 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Special Communications
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Identification of the von Hippel-Lindau (VHL) Gene

Its Role in Renal Cancer

W. Marston Linehan, MD; Michael I. Lerman, MD, PhD; Berton Zbar, MD

JAMA. 1995;273(7):564-570.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

RENAL carcinoma, the most common cancer of the kidney, occurs in over 27000 individuals in the United States each year and is responsible for over 11000 deaths annually.1 The incidence of renal carcinoma worldwide has been increasing at an annual rate of approximately 2%.1 Although renal carcinoma has been reported in children as young as 3 years, it most commonly occurs in adults between the ages of 50 and 70 years.2 Renal carcinoma affects males twice as frequently as females and accounts for approximately 3% of adult cancers. Although a number of hormonal, environmental, cellular, and genetic factors have been evaluated, little is known about the etiology of renal cancer.3 There is an increased incidence of renal cancer among workers exposed to asbestos and among leather workers,4,5 and a strong correlation has been found with cigarette smoking.6,7 In patients with end-stage renal disease, particularly . . . [Full Text PDF of this Article]


Author Affiliations

From the Urologic Oncology Section, Surgery Branch, National Cancer Institute, Bethesda, Md (Dr Linehan), and the Laboratory of Immunobiology, Frederick (Md) Cancer Research and Development Center, National Cancer Institute (Drs Lerman and Zbar).


Footnotes

Reprint requests to Urologic Oncology Section, Surgery Branch, Clinical Oncology Program, Division of Cancer Therapy, National Cancer Institute, Bldg 10, Room 2B47, 10 Center DR MSC 1502, Bethesda, MD 20892-1502 (Dr Linehan).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.